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The Breast is a huge two-volume textbook that boldly
claims to cover the comprehensive management of breast
disorders. So, does it perform as well as Google for ques-
tions and problems that crop up during a working week?
Most of us gloss over the small print in training, but in clini-
cal practice small print is often important. The larger the
textbook, the better it should be on small print topics.
A query from one of the breast care nurses: “A patient
wants to switch from tamoxifen to anastrozole because
she says that tamoxifen has ruined her singing voice. Is
that possible? If so, would anastrozole be any better?”.
Out comes the two volumes with a reassuring thump. But
the section on tamoxifen toxicity turns out to be disap-
pointingly short. There is no mention of tamoxifen’s effect
on the voice, perhaps a forgivable omission. But other
important side effects are not dealt with well. For example,
there is a brief and vague paragraph on tamoxifen eye toxi-
city, which certainly isn’t an obscure topic: breast oncolo-
gists refer patients for slit lamp examination all the time.
Later in the same week there is another rarity: a patient
with acute porphyria and newly diagnosed oestrogen
receptor-positive breast cancer. The director of the Euro-
pean Porphyria Centre turns out to be extremely helpful in
advising on drug choices by phone. He is also a steroid
biochemist with a detailed interest in sex hormones and
the exact effects of selective aromatase inhibition on each
part of the pathway, including possible differential effects
on estradiol versus estrone. Here, the chapter on
endocrine therapy of breast cancer was outstandingly
helpful; it is well written with clear diagrams on the site
and mechanism of action of aromatase inhibitors, and
includes an excellent summary of the evidence underlying
the endocrine treatment of advanced disease (although it
was odd to read that “one of the clear advantages of ful-
vestrant” is that it can only be given through deep intra-
muscular injections “since this ensures compliance”; few
patients would agree with this).
How did the textbook perform with more commonly
encountered problems? At our protocol review meeting
the question of thresholds for giving radiotherapy (RT)
after breast conserving therapy for ductal carcinoma in
situ (DCIS) comes up yet again. In common with oncolo-
gists around the world, we have had ongoing difficulties in
deciding which patients need to be given RT and which
can be treated with excision alone. The textbook deals
with this eccentrically. Mel Silverstein is given a long
chapter to make the case for the modified Van Nuys Prog-
nostic Index (VNPI), a widely used system devised by Sil-
verstein, which incorporates lesion size, patient age,
surgical margins and lesion grade to stratify patients into
different management groups. The VNPI system has been
widely adopted by surgical oncologists, but has aroused
controversy. It is good to see the system so well laid out
and explained, and there are some excellent clinical
vignettes (which would be useful for resident board exam
teaching). Although Silverstein is meticulous in presenting
the alternate view from the National Surgical Adjuvant
Breast and Bowel Project (NSABP, a clinical trials cooper-
ative group supported by the National Cancer Institute) tri-
allists that radiotherapy should usually be given for all
DCIS lesions after a local excision, the textbook is heavily
biased towards the Van Nuys approach. It seems a ques-
tionable editorial decision to give the main DCIS chapter
to one of the protagonists in an ongoing and occasionally
acrimonious debate. This whole area of breast oncology
urgently needs a magisterial overview from an indepen-
dent contributor, similar to the remarkable review that so
decisively sorted out thresholds for post mastectomy
radiotherapy (which was in a similar state of chaos a few
years ago). Perhaps Abe Recht could step up to the plate
for the next edition.
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The week ends with a heated debate at our tumour board
on the role of chemotherapy for lower risk older patients
with endocrine responsive disease. Afterwards, the text-
book comes out again. It has an excellent chapter on the
adjuvant systemic therapy of breast cancer, reviewing
exactly this problem in some detail. The authors are mod-
erate in their interpretation of the evidence. It is refresh-
ingly clear from this chapter that not all medical
oncologists in North America are blindly following NIH
Consensus recommendations.
Incidentally, it was very surprising that the textbook barely
mentions the NIH Consensus statement, with no mention
of St Gallen. In terms of its impact on clinical practice, the
NIH Consensus statement is probably the most influential
single publication in breast cancer over the past 10 years.
It has resulted in a huge expansion in the number of
patients receiving chemotherapy, and probably an
increase in the inappropriate use of chemotherapy by
under-informed (or unscrupulous) cancer physicians,
since it can be used to justify chemotherapy for virtually all
patients. The NIH Consensus statement wasn’t based on
a true consensus since it led to a deep schism in the
medical oncology community. Within a few months, seven
of the expert witnesses from the NIH meeting had recon-
vened in St Gallen to form their own panel. They drafted
an alternative Consensus, which differs markedly from the
NIH. This has had considerable influence in Europe.
Future editions of the textbook might therefore include a
chapter on decision-making, which could review the Con-
sensus statements and the controversies behind them,
together with the recent advent of hugely popular decision
support programs such as ‘Adjuvant!’, which is now in use
worldwide, and has become a major influence in consulta-
tions. This development is also not mentioned at all in the
textbook. These are major omissions. Also, perhaps some
contributors from outside the USA might be invited for
future editions (currently only one of the 146 authors is
international).
Should you buy this book? On balance, yes, if you are
physician with a substantial breast practice. Even today,
with the internet in virtually every room of the hospital, it is
reassuring to have some heavyweight textbooks to fall
back on, and despite its faults, this book has a reasonable
number of excellent chapters. It complements existing
multi-author textbooks (such as Harris) very well.
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